Developer docs
API playgroundTry for free, no card

Search company profiles

Panacea

Full company profile

uuid02ihpzp

Namestring
Panacea
Legal namestring
Panacea
Websiteurl
withpanacea.com
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Panacea is an AI-native FDA regulatory consulting firm based in San Francisco that combines a team of ex-FDA regulatory experts with custom AI tools to accelerate U.S. medical product approvals. The company supports life sciences clients across the full spectrum of FDA pathways — 510(k), De Novo, PMA, IND, NDA, and BLA — offering services spanning regulatory strategy and roadmap development, pre-FDA meeting support, end-to-end submission authoring, and quality system buildout. Its core technology positioning centers on proprietary, domain-specific AI workflows for predicate research, evidence mapping, submission structure, and technical narrative development, with the company claiming 60% faster delivery than traditional regulatory consulting firms and 100% expert oversight on all deliverables.

The company's go-to-market is sales-led and direct-to-enterprise, acquiring customers through free consultation bookings and content marketing via its website (withpanacea.com) and LinkedIn presence. Its business model is professional services with a distinctive fixed, milestone-based pricing structure — clients pay only when defined deliverables are completed rather than on hourly billing — applied to multi-year engagement contracts that align incentives across the FDA approval cycle. Its primary customer segment is medical device companies (startups to established MedTech firms), with biotech and pharma as a secondary segment for drug submission pathways.

Panacea is a privately held, founder-led company at seed stage with 1-10 employees. It raised $500,000 from Y Combinator in June 2026 and made a strategic co-investment in OutSee's £2.5M seed round in January 2026. Public customers disclosed include Adialante (mobile MRI 510(k)) and Acoustic Wave Cell Therapy (AWCT) (acoustic pulse therapy 510(k)). The senior regulatory figure is Dr. Jin Zhang, PhD, a former FDA Lead Reviewer and Team Lead serving as Principal Regulatory Affairs, with founders Haris Akhtar (CEO) and Yaman Ziadeh (CTO) leading the company.

Short descriptiontext

Panacea is an AI-native FDA regulatory consulting firm combining ex-FDA experts with custom AI tooling to accelerate medical device and biotech submissions. It serves life sciences companies across 510(k), De Novo, PMA, IND, NDA, and BLA pathways via fixed, milestone-based engagements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
FDA regulatory consulting, medical device approvals, biotech regulatory services, 510(k) submission support, AI regulatory platform
Industry2 codes
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
FDA Regulatory Consulting
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Regulatory Consulting Services
TypeProfessional Services
Description

Panacea generates revenue through milestone-based regulatory consulting engagements. Clients pay only when defined deliverables are completed, aligning incentives between the company and clients. No hourly billing. The company works on fixed pricing agreements scoped to specific regulatory milestones and timelines.

withpanacea.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Milestone-Based Fixed Pricing
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

No hourly billing. Work is scoped with defined milestones and timelines. Clients pay based on delivery of each milestone, providing risk-free, cost-predictable engagement.

withpanacea.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Panacea delivers AI-accelerated FDA regulatory consulting services that combine ex-FDA regulatory experts with proprietary AI tools to author and submit 510(k), De Novo, PMA, IND, NDA, and BLA filings. The company sells milestone-based fixed-price engagements to medical device and biotech companies, covering regulatory strategy, pre-submission engagement, full submission authoring, and quality system buildout.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 60% faster delivery than traditional regulatory consulting firms
+1 more record
Product overview1 text field

Panacea is a unified AI-native FDA regulatory platform combining ex-FDA regulatory experts with specialized AI technology. The platform integrates four core service modules: Expert-led Strategy (regulatory pathway definition and planning), End-to-end Support (full submission lifecycle management), FDA-trained AI (purpose-built AI tools for regulatory workflows), and Risk-free Pricing (fixed milestone-based billing). These components work together to deliver accelerated FDA approval across 510(k), De Novo, PMA, IND, NDA and BLA pathways.

Product and service3 records
1Panacea AI-Native FDA Regulatory Services
CategoryFDA Regulatory Consulting
Description

End-to-end AI-accelerated FDA regulatory consulting service covering strategy, pre-submission engagement, full submission authoring, and quality system buildout across 510(k), De Novo, PMA, IND, NDA, and BLA pathways, delivered under fixed milestone-based pricing for medical device and biotech companies.

2Expert-led Regulatory Strategy
CategoryRegulatory Strategy Consulting
Description

Regulatory pathway definition and milestone-driven roadmap development delivered by ex-FDA consultants with decades of combined experience across all device types, helping clients choose between 510(k), De Novo, PMA, IND, NDA, and BLA pathways.

3End-to-End FDA Submission Support
CategoryRegulatory Submission Services
Description

Full lifecycle submission support from pre-FDA meetings through end-to-end authoring and final submission, covering 510(k), De Novo, PMA, IND, NDA, and BLA filings with constant expert oversight and AI-accelerated drafting.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major CRO providing regulatory, safety, and submission support across pharma and biologics. Represents the established scale player competing for the same IND/NDA/BLA work.

TypeDirect peer
Description

Regulatory affairs management software and services for medical device and diagnostics companies. Directly comparable to Panacea's AI-driven FDA submission tooling and targets the same 510(k)/PMA workflow.

TypeDirect peer
Description

Quality management and regulatory workflow platform purpose-built for MedTech, including 510(k) and design control support. Closest SaaS-style competitor to Panacea's AI workflow platform.

TypeDirect peer
Description

Regulatory and quality consulting firm for medical device, IVD, and combination product companies. Competes with Panacea's regulatory consulting and submission-authoring services.

TypeBroad incumbent
Description

Mid-to-large CRO with regulatory affairs and clinical submission capabilities for pharma/biotech. Overlaps with Panacea's IND/NDA/BLA pathway support.

TypeEmerging player
Description

Specialty CRO focused on medical device and biotech regulatory strategy and clinical trial execution. Niche emerging competitor in the same FDA submission space.

TypeEmerging player
Description

Medical device design and regulatory services firm supporting 510(k), IDE, and PMA submissions. Comparable as a focused device-pathway regulatory specialist.

TypeBroad incumbent
Description

Global CRO offering full-service regulatory consulting and submission services. Comparable as a large, diversified alternative for life sciences regulatory work.

TypeBroad incumbent
Description

Global CRO with a large regulatory affairs and drug submission practice covering IND/NDA/BLA. Broad incumbent alternative to Panacea for biotech/pharma clients.

10Clarus Networks (regulatory consulting)
TypeEmerging player
Description

Specialized regulatory consulting firm supporting medical device and pharma companies with FDA submissions. Comparable scope to Panacea's regulatory strategy and authoring services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Panacea

FDA Regulatory Consultingwithpanacea.com

Panacea is an AI-native FDA regulatory consulting firm combining ex-FDA experts with custom AI tooling to accelerate medical device and biotech submissions. It serves life sciences companies across 510(k), De Novo, PMA, IND, NDA, and BLA pathways via fixed, milestone-based engagements.

What Panacea does

Panacea is an AI-native FDA regulatory consulting firm based in San Francisco that combines a team of ex-FDA regulatory experts with custom AI tools to accelerate U.S. medical product approvals. The company supports life sciences clients across the full spectrum of FDA pathways — 510(k), De Novo, PMA, IND, NDA, and BLA — offering services spanning regulatory strategy and roadmap development, pre-FDA meeting support, end-to-end submission authoring, and quality system buildout. Its core technology positioning centers on proprietary, domain-specific AI workflows for predicate research, evidence mapping, submission structure, and technical narrative development, with the company claiming 60% faster delivery than traditional regulatory consulting firms and 100% expert oversight on all deliverables.

The company's go-to-market is sales-led and direct-to-enterprise, acquiring customers through free consultation bookings and content marketing via its website (withpanacea.com) and LinkedIn presence. Its business model is professional services with a distinctive fixed, milestone-based pricing structure — clients pay only when defined deliverables are completed rather than on hourly billing — applied to multi-year engagement contracts that align incentives across the FDA approval cycle. Its primary customer segment is medical device companies (startups to established MedTech firms), with biotech and pharma as a secondary segment for drug submission pathways.

Panacea is a privately held, founder-led company at seed stage with 1-10 employees. It raised $500,000 from Y Combinator in June 2026 and made a strategic co-investment in OutSee's £2.5M seed round in January 2026. Public customers disclosed include Adialante (mobile MRI 510(k)) and Acoustic Wave Cell Therapy (AWCT) (acoustic pulse therapy 510(k)). The senior regulatory figure is Dr. Jin Zhang, PhD, a former FDA Lead Reviewer and Team Lead serving as Principal Regulatory Affairs, with founders Haris Akhtar (CEO) and Yaman Ziadeh (CTO) leading the company.

Panacea firmographics

Firmographics
Name
Panacea
Legal name
Panacea
Website
https://withpanacea.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
1–10 employees
Short description
Panacea is an AI-native FDA regulatory consulting firm combining ex-FDA experts with custom AI tooling to accelerate medical device and biotech submissions. It serves life sciences companies across 510(k), De Novo, PMA, IND, NDA, and BLA pathways via fixed, milestone-based engagements.
Ownership category
akta.pro rank

Panacea industry classification

Industry
Product category
FDA Regulatory Consulting
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs

Keywords

  • FDA regulatory consulting
  • Medical device approvals
  • Biotech regulatory services
  • 510(k) submission support
  • AI regulatory platform

Where Panacea is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Panacea business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Regulatory Consulting Services: Panacea generates revenue through milestone-based regulatory consulting engagements. Clients pay only when defined deliverables are completed, aligning incentives between the company and clients. No hourly billing. The company works on fixed pricing agreements scoped to specific regulatory milestones and timelines.

Pricing tiers

ModelBillingPrice
Outcome Based/ PerformanceMulti-year contractMilestone-Based Fixed Pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Panacea product offering

Product offering

Core offering

Panacea delivers AI-accelerated FDA regulatory consulting services that combine ex-FDA regulatory experts with proprietary AI tools to author and submit 510(k), De Novo, PMA, IND, NDA, and BLA filings. The company sells milestone-based fixed-price engagements to medical device and biotech companies, covering regulatory strategy, pre-submission engagement, full submission authoring, and quality system buildout.

Product overview

Panacea is a unified AI-native FDA regulatory platform combining ex-FDA regulatory experts with specialized AI technology. The platform integrates four core service modules: Expert-led Strategy (regulatory pathway definition and planning), End-to-end Support (full submission lifecycle management), FDA-trained AI (purpose-built AI tools for regulatory workflows), and Risk-free Pricing (fixed milestone-based billing). These components work together to deliver accelerated FDA approval across 510(k), De Novo, PMA, IND, NDA and BLA pathways.

Differentiator

Problem solved

Functional benefit

Products and services

  • Panacea AI-Native FDA Regulatory Services End-to-end AI-accelerated FDA regulatory consulting service covering strategy, pre-submission engagement, full submission authoring, and quality system buildout across 510(k), De Novo, PMA, IND, NDA, and BLA pathways, delivered under fixed milestone-based pricing for medical device and biotech companies.
  • Expert-led Regulatory Strategy Regulatory pathway definition and milestone-driven roadmap development delivered by ex-FDA consultants with decades of combined experience across all device types, helping clients choose between 510(k), De Novo, PMA, IND, NDA, and BLA pathways.
  • End-to-End FDA Submission Support Full lifecycle submission support from pre-FDA meetings through end-to-end authoring and final submission, covering 510(k), De Novo, PMA, IND, NDA, and BLA filings with constant expert oversight and AI-accelerated drafting.

Quantifiable outcome

  • 60% faster delivery than traditional regulatory consulting firms
  • +1 more outcomes

Companies that use Panacea

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Panacea technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Panacea partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Panacea competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Major CRO providing regulatory, safety, and submission support across pharma and biologics. Represents the established scale player competing for the same IND/NDA/BLA work.
  • Medpace: Mid-to-large CRO with regulatory affairs and clinical submission capabilities for pharma/biotech. Overlaps with Panacea's IND/NDA/BLA pathway support.
  • ICON plc: Global CRO offering full-service regulatory consulting and submission services. Comparable as a large, diversified alternative for life sciences regulatory work.
  • IQVIA: Global CRO with a large regulatory affairs and drug submission practice covering IND/NDA/BLA. Broad incumbent alternative to Panacea for biotech/pharma clients.

Direct peers

  • Rimsys: Regulatory affairs management software and services for medical device and diagnostics companies. Directly comparable to Panacea's AI-driven FDA submission tooling and targets the same 510(k)/PMA workflow.
  • Greenlight Guru: Quality management and regulatory workflow platform purpose-built for MedTech, including 510(k) and design control support. Closest SaaS-style competitor to Panacea's AI workflow platform.
  • MethodSense: Regulatory and quality consulting firm for medical device, IVD, and combination product companies. Competes with Panacea's regulatory consulting and submission-authoring services.

Emerging players

  • Proxima Clinical Research: Specialty CRO focused on medical device and biotech regulatory strategy and clinical trial execution. Niche emerging competitor in the same FDA submission space.
  • StarFish Medical: Medical device design and regulatory services firm supporting 510(k), IDE, and PMA submissions. Comparable as a focused device-pathway regulatory specialist.
  • Clarus Networks (regulatory consulting): Specialized regulatory consulting firm supporting medical device and pharma companies with FDA submissions. Comparable scope to Panacea's regulatory strategy and authoring services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Panacea social profiles

Digital presence

Panacea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Panacea leadership team

Management profile

Number of profiles

Profiles3 records

Panacea funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Panacea M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Panacea

What does Panacea do?

Panacea delivers AI-accelerated FDA regulatory consulting services that combine ex-FDA regulatory experts with proprietary AI tools to author and submit 510(k), De Novo, PMA, IND, NDA, and BLA filings. The company sells milestone-based fixed-price engagements to medical device and biotech companies, covering regulatory strategy, pre-submission engagement, full submission authoring, and quality system buildout.

Is Panacea a public or private company?

Panacea is a private company. It is classified as venture growth investor backed and is currently operating.

When was Panacea founded?

Panacea was founded in 2026. It employs 1 to 10 people.

Where is Panacea based?

Panacea is headquartered in San Francisco, United States, in the North America region.

How does Panacea make money?

One revenue line is on record: regulatory Consulting Services.

Who are Panacea's main competitors?

Broad incumbents on record are Charles River Laboratories, Medpace, ICON plc and IQVIA. Direct peers are Rimsys, Greenlight Guru and MethodSense. Emerging players are Proxima Clinical Research, StarFish Medical and Clarus Networks (regulatory consulting).

Does Panacea have an API?

No public API is recorded for Panacea.

What industry is Panacea in?

Panacea's product category is FDA Regulatory Consulting. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAGAAAH, Pharmacovigilance, Risk Management & Medical Affairs CROs. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals